On June 12, 2017, TheraMind Center of Santa Barbara announced our role in a collaborative clinical research project with Westmont College. This Independent Review Board (IRB) approved study, under the direction of Westmont’s neuropsychopharmacologist, Dr. Ronald See, aims to evaluate [..]
New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System(R) induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder (MDD) during the acute phase of therapy, which were maintained through one year of treatment. At the end of acute treatment, 62 percent of patients achieved symptomatic improvement while 41 percent reported complete remission. At 12 months, 68 percent of patients achieved symptomatic improvement while 45 percent reported complete remission. Maintenance of benefit was observed under a pragmatic regimen of continuation antidepressant medication and access to TMS reintroduction for symptom recurrence.